Motor complications of chronic levodopa therapy in Parkinson's disease

Clinical Neuropharmacology

Volumn 20, Issue 6, 1997, Pages 523-530

  Miyawaki, Edison ^a   Lyons, Kelly ^a   Pahwa, Rajesh ^a   Tröster, Alexander I ^a   Hubble, Jean ^b   Smith, Diane ^a   Busenbark, Karen ^a   McGuire, Desni ^a   Michalek, Debra ^a   Koller, William C ^a  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^b THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

Author keywords

Induced dyskinesia; Levodopa; Motor fluctuations; Parkinson's disease

Indexed keywords

LEVODOPA;

ADOLESCENT; ARTICLE; CHILD; DYSKINESIA; DYSTONIA; HUMAN; INFANT; MAJOR CLINICAL STUDY; MOTOR DYSFUNCTION; ORAL DRUG ADMINISTRATION; PARKINSON DISEASE; PRIORITY JOURNAL; SYMPTOMATOLOGY;

EID: 0030784938     PISSN: 03625664     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002826-199712000-00004     Document Type: Article

References (34)

1. Poewe WH. Clinical aspects of motor fluctuations in Parkinson's disease. Neurol 1994;44(suppl 6):6-9.
2. Marsden CD, Parkes JD, Quinn N. Fluctuation of disability in Parkinson's disease - clinical aspects. In: Marsden CD, Fahn S, eds. Movement Disorders. Butterworths International Medical Reviews, Neurology 2. London: Butterworth; 1982:96-122.
3. Hardie RJ, Lees AJ, Stern GM. On-off fluctuations in Parkinson's disease. Brain 1984;107:487-506.
4. Nutt JG. Levodopa-induced dyskinesia: review, observations, and speculations. Neurol 1990;40:340-5.
5. Melamed E. Early-morning dystonia: a late side effect of long term levodopa therapy in Parkinson's disease. Arch Neurol 1979;36:308-10.
6. Poewe WH, Wenning GK. The natural history of Parkinson's disease. Neurol 1996;47(suppl 3):146-52.
7. Fahn S. Is levodopa toxic? Neurol 1996;47(suppl 3):184-95.
8. Marsden CD, Parkes JD. "On-off" effects in patients with Parkinson's disease on chronic levodopa therapy. Lancet 1976;1:292-6.
9. Duvoisin RC. To treat early or to treat late? [Editorial]. Ann Neurol 1987;22:2-3.
10. Lee JE, Sweet RD, McDowell FH. Treatment of Parkinsonism with levodopa. Follow-up after 2 years of treatment. Ann Intern Med 1971;75:703-8.
11. Sweet RD, McDowell FH. Five years' treatment of Parkinson's disease with levodopa. Therapeutic results and survival of 100 patients. Ann Intern Med 1975;83:456-63.
12. Barbeau A. Six years of high-level levodopa therapy in severely akinetic Parkinsonian patients. Arch Neurol 1976;33:333-8.
13. Barbeau A, Roy M. Six-year results of treatment with levodopa plus benzerazide in Parkinson's disease. Neurol 1976;26:399-404.
14. Shaw KM, Lees AJ, Stern GM. The impact of treatment with levodopa on Parkinson's disease. Q J Med 1980;49:283-93.
15. Rajput AH, Stern W, Laverty WH. Chronic low-dose levodopa therapy in Parkinson's disease: an argument for delaying levodopa therapy. Neurol 1984;34:991-6.
16. Poewe WH, Lees AJ, Stern GM. Low-dose L-dopa therapy in Parkinson's disease: a 6-year follow-up study. Neurol 1986;36:1528-30.
17. Fahn S. Adverse effects of levodopa. In: Olanow CW, Lieberman AN, eds. The Scientific Basis for the Treatment of Parkinson's Disease. Carnforth: Parthenon Publishing Group; 1992:89-112.
18. Fahn S, Elton RL, members of the UPDRS Development Committee. Unified Parkinson's Disease Rating Scale. In: Fahn S, Marsden CD, Calne DB, Goldstein M, eds. Recent Developments in Parkinson's Disease. Vol. 2. Florham Park, NJ: MacMillan Health Care Information; 1987:153-64.
19. Hoehn MM, Yahr MD. Parkinsonism: onset, progression, and mortality. Neurol 1967;17:427-42.
20. Schwab RS, England AC. Projection technique for evaluating surgery in Parkinson's disease. In: Gillingham FJ, Donaldson MC, eds. Third Symposium on Parkinson's Disease. Edinburgh: E. & S. Livingstone; 1969.
21. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state": a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-98.
22. Lesser RP, Fahn S, Snider SR, Cote LJ, Isgreen WP, Barrett RE. Analysis of the clinical problems in parkinsonism and the complications of long-term levodopa therapy. Neurol 1979;29:1252-60.
23. Markham CH, Diamond SG. Evidence to support early levodopa therapy in Parkinson's disease. Neurol 1981;31:125-31.
24. Markham CH, Diamond SG. Long-term follow-up of early dopa treatment in Parkinson's disease. Ann Neurol 1986;19:365-72.
25. Golbe LI. Young-onset Parkinson's disease: a clinical review. Neurol 1991;41:169-73.
26. Roos RAC, Vredevoogd CB, van der Velde EA. Response fluctuations in Parkinson's disease. Neurol 1990;40:1344-6.
27. Blin J, Bonnet AM, Agid Y. Does levodopa aggravate Parkinson's disease? Neurol 1988;38:1410-6.
28. Lee CS, Schulzer M, Mak EK, et al. Clinical observations on the rate of progression of idiopathic Parkinsonism. Brain 1994;117:501-7.
29. Maier Hoehn MM. The natural history of Parkinson's disease in the pre-levodopa and post-levodopa eras. Neurol Clin 1992;10:331-9.
30. Hughes AJ, Ben-Schlomo YB, Daniel SE, Lees AJ. What features improve the accuracy of clinical diagnosis in Parkinson's disease: a clinicopathologic study. Neurol 1992;42:1142-6.
31. Hughes AJ, Daniel SE, Kilford L, Lees AJ. The accuracy of diagnosis of idiopathic Parkinson's disease: a clinicopathologic study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55:181-4.
32. Goetz CG, Stebbins GT. Risk factors for nursing home placement in advanced Parkinson's disease. Neurol 1993;43:2227-9.
33. Cedarbaum JM, Gandy SE, McDowell FH. "Early" initiation of levodopa treatment does not promote the development of motor response fluctuations, dyskinesias, or dementia in Parkinson's disease. Neurol 1991;41:622-9.
34. Caraceni T. A case for early levodopa treatment of Parkinson's disease. Clin Neuropharmacol 1994;17 (suppl):38-42.